I agree that it's certainly in the company's best interest to...

I agree that it's certainly in the company's best interest to use this extended time wisely to give all shareholders a firm reason as to why they should be committing to the rights issue.

Maybe some insight in to the following may be in the company's best interest:
- A formal update as to how the FDA question responses are progressing and when the company is intending on having this responses submitted?
- How the 510K application is progressing? Can the company confirm when this is due to be submitted or if it formally has been submitted?
- Are there any plans being drafted to commercialise in the regions the company has formal product approval? If so, it would be worth sharing these with the market.
- Any updates from the Corporate business? Contract developments etc?

If the company is extending the rights issue hoping that shareholders will find the lose change in the back of the couch to airmail it over, they are kidding themselves. The price of the rights issue is not a determining factor for those who have not committed funds at this point in time.

The longer this stays open, the longer the drag / perceived overhang on market.